Brenipatide + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking
Conditions
Smoking
Trial Timeline
Nov 3, 2025 → Feb 1, 2027
NCT ID
NCT07223840About Brenipatide + Placebo
Brenipatide + Placebo is a phase 2 stage product being developed by Eli Lilly for Smoking. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07223840. Target conditions include Smoking.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07412756 | Phase 3 | Recruiting |
| NCT07410507 | Phase 2 | Recruiting |
| NCT07286175 | Phase 2 | Recruiting |
| NCT07223840 | Phase 2 | Recruiting |
Competing Products
20 competing products in Smoking